Close Menu

NEW YORK (GenomeWeb) – Transgenomic today announced that it has non-exclusively licensed its portfolio of intellectual property related to DNA susceptibility testing for long QT syndrome to Laboratory Corporation of America.

Long QT syndrome is a primarily congenital heart rhythm disorder associated with cardiac arrhythmia and can be triggered by prescription medicines in individuals prone to the condition.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.